Non-Current Assets

Vertex Pharmaceuticals·Balance Sheet Statement·15 metrics

Breakdown

Metric	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Total assets	$20.1B	$22.2B	$22.5B	$22.9B	$24.0B	$24.9B	$25.6B	$26.5B
Long- term Investments	$4.4B	$4.7B	$5.1B	$5.2B	$5.6B	$5.7B	$5.7B	$5.7B
Deferred tax assets	$2.2B	$2.3B	$2.3B	$2.5B	$2.7B	$2.9B	$2.9B	$2.9B
Net Investment in Lease	$569.8M	$1.4B	$1.4B	$1.3B	$1.3B	$1.6B	$1.6B	$1.7B
Operating lease right-of-use assets	$569.8M	$1.4B	$1.4B	$1.3B	$1.3B	$1.6B	$1.6B	$1.7B
Operating Lease Right-of-Use Assets in Other Assets	$569.8M	$1.4B	$1.4B	$1.3B	$1.3B	$1.6B	$1.6B	$1.7B
Property, plant and equipment, net	$1.2B	$1.1B	$1.2B	$1.3B	$1.3B	$1.4B	$1.5B	$1.6B
Deferred Tax Assets and Other Non-Current Assets	$915.6M	$990.2M	$999.3M	$1.0B	$1.1B	$1.1B	$1.2B	$1.3B
Other non-current assets	$915.6M	$990.2M	$999.3M	$1.0B	$1.1B	$1.1B	$1.2B	$1.3B
Software and Technology Licenses, Net	$915.6M	$990.2M	$999.3M	$1.0B	$1.1B	$1.1B	$1.2B	$1.3B
Goodwill	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B
Other intangible assets—net	$837.5M	$831.6M	$825.9M	$441.2M	$435.5M	$429.8M	$424.2M	$418.5M
Equity Amortized Cost	$72.1M	$72.1M	$72.1M	$60.0M	$60.0M	$25.0M	$25.0M	$25.0M
Investments - Cost Basis	$72.1M	$72.1M	$72.1M	$60.0M	$60.0M	$25.0M	$25.0M	$25.0M
Equity securities	$30.6M	$33.4M	$36.6M	$21.6M	$27.9M	$9.4M	$16.6M	$20.4M